$24.07
+0.22
(+0.92%)▲
Insights on Alkermes Plc
Revenue is down for the last 3 quarters, 617.39M → 377.47M (in $), with an average decrease of 19.6% per quarter
Netprofit is up for the last 2 quarters, 47.75M → 112.77M (in $), with an average increase of 57.7% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 28.3% return, outperforming this stock by 46.4%
In the last 3 years, Neurocrine Biosciences Inc. has given 38.2% return, outperforming this stock by 25.1%
1.25%
Downside
Day's Volatility :1.7%
Upside
0.45%
8.56%
Downside
52 Weeks Volatility :34.71%
Upside
28.6%
Period | Alkermes Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.66% | -0.4% | 0.0% |
6 Months | -1.47% | 9.6% | 0.0% |
1 Year | -17.51% | 3.9% | -1.3% |
3 Years | 13.11% | 12.8% | -22.1% |
Market Capitalization | 4.0B |
Book Value | $7.2 |
Earnings Per Share (EPS) | 3.06 |
PE Ratio | 7.79 |
PEG Ratio | -1057.29 |
Wall Street Target Price | 35.55 |
Profit Margin | 21.39% |
Operating Margin TTM | 14.47% |
Return On Assets TTM | 12.81% |
Return On Equity TTM | 46.22% |
Revenue TTM | 1.7B |
Revenue Per Share TTM | 10.01 |
Quarterly Revenue Growth YOY | 23.9% |
Gross Profit TTM | 893.7M |
EBITDA | 495.0M |
Diluted Eps TTM | 3.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 2.78 |
EPS Estimate Next Year | 2.67 |
EPS Estimate Current Quarter | 0.51 |
EPS Estimate Next Quarter | 0.61 |
What analysts predicted
Upside of 47.69%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 21.13% |
Net Income | -139.3M | ↓ 11.8% |
Net Profit Margin | -12.73% | ↑ 4.75% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 7.01% |
Net Income | -196.6M | ↑ 41.14% |
Net Profit Margin | -16.79% | ↓ 4.06% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↓ 11.29% |
Net Income | -110.9M | ↓ 43.62% |
Net Profit Margin | -10.67% | ↑ 6.12% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 13.0% |
Net Income | -48.2M | ↓ 56.55% |
Net Profit Margin | -4.1% | ↑ 6.57% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 5.28% |
Net Income | -158.3M | ↑ 228.57% |
Net Profit Margin | -14.24% | ↓ 10.14% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 49.61% |
Net Income | 355.8M | ↓ 324.78% |
Net Profit Margin | 21.39% | ↑ 35.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 252.4M | ↓ 8.64% |
Net Income | -64.0M | ↑ 112.28% |
Net Profit Margin | -25.35% | ↓ 14.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 304.7M | ↑ 20.73% |
Net Income | -28.3M | ↓ 55.84% |
Net Profit Margin | -9.27% | ↑ 16.08% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 287.6M | ↓ 5.61% |
Net Income | -41.8M | ↑ 48.1% |
Net Profit Margin | -14.55% | ↓ 5.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 617.4M | ↑ 114.68% |
Net Income | 237.1M | ↓ 666.53% |
Net Profit Margin | 38.4% | ↑ 52.95% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 380.9M | ↓ 38.3% |
Net Income | 47.8M | ↓ 79.85% |
Net Profit Margin | 12.54% | ↓ 25.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 377.5M | ↓ 0.91% |
Net Income | 112.8M | ↑ 136.15% |
Net Profit Margin | 29.88% | ↑ 17.34% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 1.55% |
Total Liabilities | 653.7M | ↑ 9.98% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 1.07% |
Total Liabilities | 720.0M | ↑ 10.13% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 7.99% |
Total Liabilities | 882.7M | ↑ 22.61% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 3.83% |
Total Liabilities | 911.9M | ↑ 3.3% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 2.99% |
Total Liabilities | 920.2M | ↑ 0.91% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 8.77% |
Total Liabilities | 933.5M | ↑ 1.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↓ 0.79% |
Total Liabilities | 899.0M | ↑ 2.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↑ 1.14% |
Total Liabilities | 920.2M | ↑ 2.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↓ 2.1% |
Total Liabilities | 917.2M | ↓ 0.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 13.75% |
Total Liabilities | 906.7M | ↓ 1.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 4.21% |
Total Liabilities | 923.6M | ↑ 1.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 6.27% |
Total Liabilities | 933.5M | ↑ 1.07% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 99.3M | ↑ 417.36% |
Investing Cash Flow | -22.2M | ↑ 20.91% |
Financing Cash Flow | -1.6M | ↓ 139.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 72.1M | ↓ 27.4% |
Investing Cash Flow | -141.8M | ↑ 539.03% |
Financing Cash Flow | 6.8M | ↓ 517.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 82.8M | ↑ 14.94% |
Investing Cash Flow | -11.5M | ↓ 91.91% |
Financing Cash Flow | -2.2M | ↓ 132.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 101.7M | ↑ 22.78% |
Investing Cash Flow | -66.2M | ↑ 476.64% |
Financing Cash Flow | 29.1M | ↓ 1439.11% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 21.0M | ↓ 79.31% |
Investing Cash Flow | -64.5M | ↓ 2.51% |
Financing Cash Flow | -1.6M | ↓ 105.41% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 625.0K | ↓ 127.1% |
Investing Cash Flow | 8.9M | ↓ 121.95% |
Financing Cash Flow | -212.0K | ↓ 101.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.0M | ↑ 67.52% |
Investing Cash Flow | 27.7M | ↑ 211.76% |
Financing Cash Flow | -271.0K | ↑ 27.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.3M | ↓ 2134.57% |
Investing Cash Flow | 72.9M | ↑ 162.62% |
Financing Cash Flow | -22.6M | ↑ 8246.86% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 215.7M | ↓ 1112.63% |
Investing Cash Flow | -119.4M | ↓ 263.84% |
Financing Cash Flow | 7.8M | ↓ 134.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 99.7M | ↓ 53.78% |
Investing Cash Flow | -119.4M | ↑ 0.0% |
Financing Cash Flow | 1.6M | ↓ 80.0% |
Sell
Neutral
Buy
Alkermes Plc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Alkermes Plc | -11.86% | -1.47% | -17.51% | 13.11% | -29.68% |
Neurocrine Biosciences Inc. | -4.7% | 23.86% | 29.07% | 38.18% | 65.61% |
Haleon Plc Spon Ads | -0.83% | 1.09% | -6.49% | 12.82% | 12.82% |
Zoetis Inc. | -13.27% | -12.59% | -17.47% | -14.66% | 42.73% |
Viatris Inc. | -4.9% | 26.12% | 20.58% | -15.79% | -31.15% |
Catalent, Inc. | -0.62% | 32.76% | 24.72% | -51.21% | 26.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Alkermes Plc | 7.79 | 7.79 | -1057.29 | 2.78 | 0.46 | 0.13 | NA | 7.2 |
Neurocrine Biosciences Inc. | 53.44 | 53.44 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.36 | 29.36 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 28.82 | 28.82 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 222.4 | 222.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Alkermes Plc | Buy | $4.0B | -29.68% | 7.79 | 21.39% |
Neurocrine Biosciences Inc. | Buy | $13.3B | 65.61% | 53.44 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.5B | 12.82% | 29.36 | 9.28% |
Zoetis Inc. | Buy | $66.8B | 42.73% | 28.82 | 27.43% |
Viatris Inc. | Hold | $13.2B | -31.15% | 222.4 | 0.35% |
Catalent, Inc. | Hold | $10.0B | 26.1% | 211.02 | -31.77% |
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
State Street Corporation
Sarissa Capital Management LP
Renaissance Technologies Corp
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Organization | Alkermes Plc |
Employees | 2100 |
CEO | Mr. Richard F. Pops |
Industry | Health Technology |
Arvinas Inc
$24.07
+0.92%
Spirit Aerosystems Holdings, Inc.
$24.07
+0.92%
Brazil Capped Etf Msci Ishares
$24.07
+0.92%
Fidelity High Dividend Etf
$24.07
+0.92%
Spdr Bloomberg Barclays Intermediate Term Corp Bond Etf
$24.07
+0.92%
Alerian Mlp Etf Alps
$24.07
+0.92%
Global X Us Preferred Etf
$24.07
+0.92%
Capital Group Global Growth
$24.07
+0.92%
Nio Inc.
$24.07
+0.92%